



**HAL**  
open science

## Recent advances in understanding inheritance of Holoprosencephaly

Christèle Dubourg, Artem Kim, Erwan Watrin, Marie de Tayrac, Sylvie Odent, Véronique David, Valérie Dupé

► **To cite this version:**

Christèle Dubourg, Artem Kim, Erwan Watrin, Marie de Tayrac, Sylvie Odent, et al.. Recent advances in understanding inheritance of Holoprosencephaly. *American Journal of Medical Genetics Part C Seminar in Medical Genetics*, 2018, Holoprosencephaly, 178 (2), pp.258-269. 10.1002/ajmg.c.31619 . hal-01812521v1

**HAL Id: hal-01812521**

**<https://univ-rennes.hal.science/hal-01812521v1>**

Submitted on 4 Sep 2018 (v1), last revised 14 Sep 2018 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Recent advances in understanding inheritance of Holoprosencephaly

Christèle Dubourg<sup>1,2</sup>, Artem Kim<sup>1</sup>, Erwan Watrin<sup>1</sup>, Marie de Tayrac<sup>1,2</sup>, Sylvie Odent<sup>1,3</sup>,  
Véronique David<sup>\*1,2</sup>, Valérie Dupé<sup>1</sup>.

1 - Univ Rennes, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, F - 35000  
Rennes, France

2 - Service de Génétique Moléculaire et Génomique, CHU, Rennes, France.✉

3 - Service de Génétique Clinique, CHU, Rennes, France.✉

\* to whom correspondence should be addressed

veronique.david@univ-rennes1.fr

Christèle Dubourg, Pharm.D, PhD, is a molecular geneticist, with a specific interest in the field of developmental anomalies (intellectual deficiency, holoprosencephaly), and in charge of molecular diagnoses of these diseases in the Laboratory of Molecular Genetics and Genomics at the University Hospital of Rennes.

Artem Kim is a data scientist specialized in clinical NGS data analysis. He is currently working toward his PhD, which focuses on genetic basis of holoprosencephaly.

Erwan Watrin holds a PhD in Biological Sciences and is principal investigator at the French CNRS (Centre National de la Recherche Scientifique). His work focuses on chromosome biology and its relevance to developmental disorders with a particular interest for cohesinopathies.

Marie de Tayrac, PhD, is head of the Laboratory of Bioinformatics and Computational Genetics at the University Hospital of Rennes. Her research activities at the Institute of Genetics and Development of Rennes focus on deciphering the genetic basis of human diseases using bioinformatics and systems biology approaches.

Sylvie Odent, MD, PhD is a Clinical Geneticist, head of the department and is responsible for the teaching of genetics at the Faculty of Medicine of Rennes. Her research projects focus on neurodevelopmental syndromes, with a special interest in brain malformations (Holoprosencephaly) and rare diseases of development. She coordinates an accredited center of expertise in the west of France (CLAD-Ouest) and is a member of the European Reference Network ITHACA.

Véronique David, Pharm PhD, is head of the Laboratory of Molecular Genetics and Genomics at the University Hospital of Rennes. She is also head of the research team « Genetics of pathologies related to development » at the Institute of Genetics and Development of Rennes, aiming at studying the genetics and physiopathology of complex developmental diseases.

1  
2  
3  
4 Valérie Dupé, PhD, is a research scientist at Inserm (Institut national de la santé et de la recherche médicale).  
5 After having acquired a strong background in vertebrate development at the IGBMC (Strasbourg, France) and  
6 UCL (London), she has joined the Institute of Genetics and Development of Rennes (IGDR) to study brain  
7 development with a special interest in Holoprosencephaly.  
8  
9

## 10 11 12 13 14 15 16 **Abstract**

17  
18 Holoprosencephaly (HPE) is a complex genetic disorder of the developing forebrain characterized by  
19 high phenotypic and genetic heterogeneity. HPE was initially defined as an autosomal dominant  
20 disease, but recent research has shown that its mode of transmission is more complex. The past  
21 decade has witnessed rapid development of novel genetic technologies and significant progresses in  
22 clinical studies of HPE. In this review, we recapitulate genetic epidemiological studies of the largest  
23 European HPE cohort and summarize the novel genetic discoveries of HPE based on recently  
24 developed diagnostic methods. Our main purpose is to present different inheritance patterns that  
25 exist for HPE with a particular emphasis on oligogenic inheritance and its implications in genetic  
26 counseling.  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **INTRODUCTION**

37  
38 Holoprosencephaly is a severe developmental disorder classically defined as incomplete cleavage of  
39 the forebrain that originates from failed midline delineation during early development. There are  
40 several degrees of severity defined by the extent of the brain malformations. For the most severe  
41 cases, malformations are divided into alobar, semilobar or lobar forms. These brain abnormalities are  
42 associated with facial anomalies that are also of varying severity ranging from cyclopia to milder signs  
43 such as ocular hypotelorism. The full spectrum of HPE also includes microforms characterized by  
44 facial midline defects (e.g., single median incisor) without brain malformations typical of HPE (Cohen,  
45 2006; Dubourg et al., 2007; Hahn, Barnes, Clegg, & Stashinko, 2010; Muenke & Beachy, 2000).  
46  
47 HPE occurs in most ethnic groups worldwide. Although implication of maternal diabetes in HPE has  
48 been reported (Barr et al., 1983), the well-established origin of HPE remains almost exclusively  
49 genetic and consists of chromosomal abnormalities and nucleotide-based variants (Dubourg et al.,  
50 2007, 2016; Solomon et al., 2012). So far, 17 genes have been implicated in HPE, all of which encode  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 proteins belonging to brain development pathways. *Sonic Hedgehog (SHH)* was the first discovered  
4 HPE gene (Roessler et al., 1996) and its alterations remain the most common cause of non-  
5 chromosomal HPE (Dubourg et al., 2016). *SHH* has been extensively studied and its functions during  
6 early brain development are now well described. A morphogenetic gradient of SHH is established  
7 from the ventral midline of the diencephalon to induce appropriate cleavage of both forebrain and  
8 eyefield. Remarkably, all HPE genes described so far are involved in the regulation of SHH activity  
9 (Sun et al., 2014; Xavier et al., 2016).  
10  
11  
12  
13

14  
15 Initially described as an autosomal dominant trait with incomplete penetrance and variable  
16 expressivity, the mode of inheritance of HPE has been progressively redefined. The apparent  
17 autosomal dominant transmission with incomplete penetrance observed in a few HPE families may  
18 well be due to the cumulative effects of rare variants in two genes or more. Undeniably, the  
19 prevalence of oligogenicity has increased for several developmental pathologies since Next  
20 Generation Sequencing (NGS) technologies became accessible (Bamshad et al., 2011). Despite  
21 technical advances, defining the causative gene for HPE remains a difficult task, and even when one  
22 underlying variant is known, prenatal prediction remains uncertain.  
23  
24  
25  
26  
27

28 Here, we describe clinical features and inheritance aspects of this disease with examples from our  
29 experience.  
30  
31  
32

### 33 **Clinical and genetics features of the cohort**

#### 34 **The European HPE cohort**

35  
36  
37 In 1996, a European HPE network was established in Rennes, France. Patients are recruited by  
38 clinicians from the different French centers of reference for rare developmental diseases as well as  
39 from several European clinical centers in the UK, Belgium, Italy, Spain and Portugal. Half of collected  
40 samples were fetuses, which enriched our cohort for severe HPE phenotypes (Mercier et al., 2011).  
41 Over the years, we have collected over 2,700 blood DNA samples or frozen fetal tissues, including  
42 patients and relatives, and gathered clinical data and DNA for 1,420 HPE probands. Our cohort  
43 contains both apparently sporadic and familial cases, excluding those associated with other  
44 malformation syndromes or with known chromosomal abnormalities that could be revealed by  
45 standard cytogenetic analysis (e.g., trisomies 18 and 13).  
46  
47  
48  
49  
50  
51  
52  
53

54 HPE presents a wide continuous spectrum of clinical malformations ranging from severe to milder  
55 forms. Our cohort is representative of the full clinical spectrum of HPE phenotypes (Mercier et al.,  
56  
57  
58  
59  
60

2011). Within this cohort, the most severe brain malformations are categorized into alobar, semilobar or lobar form. Middle interhemispheric fissure (syntelencephaly) - incomplete separation of the posterior frontal and parietal regions - also belongs to the HPE spectrum (Figure 1). These brain abnormalities are significantly correlated with a variety of distinct facial anomalies ranging from cyclopia, the most severe form, to milder signs such as ocular hypotelorism. Severe facial phenotypes, such as cyclopia, ethmocephaly (proboscis) and cebocephaly are more highly associated with alobar HPE. Similarly, premaxillary agenesis, cleft lip or palate and milder ocular abnormalities (coloboma, retinal dysplasia) are mostly associated with semilobar HPE while the mild midface malformations, such as pyriform sinus stenosis and choanal stenosis are mostly found in lobar HPE. Patients who present the mildest facial abnormalities, such as hypotelorism, cleft lip or single median incisor, generally do not present easily detectable brain malformations (Mercier et al., 2011). These HPE microforms can nonetheless be associated with microcephaly and intellectual disability and their molecular diagnosis is therefore important for proper patient care (Bruehl et al., 2017; Solomon et al., 2010). Notably, most of these microforms have been diagnosed only because they were relatives of patients with severe HPE. Some families manifest a wide range of phenotypes, from typical alobar HPE with perinatal lethality to microforms such as microcephaly, hypotelorism or both (Mercier et al., 2011). These different observations and clinical correlations made on a European cohort can be extended to all HPE cohorts, as they are very similar to those of North American patients (Lacabawan et al., 2009; Solomon et al., 2010).

As the frequency of microform HPE is underestimated, we are currently expanding our diagnostic approach to mildly affected relatives of a classical HPE patient. When a typical HPE patient is diagnosed in a family, we routinely perform a careful examination of all family members including neuroimaging techniques (MRI) and determination of clinical features that are not traditionally considered as a part of the HPE spectrum. Our goal is to expand our cohort to a larger number of HPE microforms to ensure that we cover the entire HPE spectrum.

### **The evolution of genetic strategies for HPE diagnosis**

#### *Sanger sequencing and detection of microdeletions in the major HPE genes*

From the discovery of the first genes responsible for HPE until recently, genetic analysis of HPE patients has mainly relied on a Sanger sequencing approach (Mercier et al., 2011). During that period (1997 to 2010), screening our cohort for nucleotide-based variants in the four HPE genes – *SHH*, *Zinc Finger Protein 2 (ZIC2)*, *Six Homeobox 3 (SIX3)* and the Homeobox protein *TGIF1* – provided a global variant detection rate of 20 % (8.2 % for *SHH*, 7.4 % for *ZIC2*, 3.9 % for *SIX3* and 1.1 % for *TGIF1* (Mercier et al., 2011). All variants in these genes were detected heterozygously, and were shown to be loss-of-function variants (Roessler, El-Jaick, et al., 2009; Roessler, Lacabawan, et al., 2009). These

1  
2  
3 genes have constituted the four major genes of HPE. Meanwhile, novel genes have been implicated  
4 in sporadic cases of HPE (Table II and Roessler, El-Jaick, et al., 2009). The implication of each gene  
5 represents less than 1 % of HPE patients and they are therefore referred to as minor genes.

6  
7 In 2003, variants in *GLI2*, one crucial effector of SHH signaling pathway (Ruiz i Altaba, Palma, &  
8 Dahmane, 2002), had been described in HPE patients (Roessler et al., 2003), and screening of our  
9 cohort (Figure 1) revealed *GLI2* variants in 3.2 % of the 302 patients tested (Mercier et al., 2011), thus  
10 placing *GLI2* as a major gene.  
11

12  
13 Identification of variants combined with detailed clinical assessment of HPE patients has allowed  
14 establishing some genotype-phenotype correlations (Mercier et al., 2011; Solomon et al., 2010). The  
15 most severe types of HPE (alobar and semilobar) tend to be associated with *ZIC2* and *SIX3* alterations  
16 while *SHH* tends to be more frequently associated with microforms. Remarkably, in *SHH* and *SIX3*  
17 cases, the facial dysmorphism is associated with brain anomalies while the probands of the *ZIC2*  
18 group tend to have a combination of severe HPE with few of the facial features. *GLI2* variants were  
19 preferentially found in patients presenting HPE microforms together with secondary specific features  
20 such as pituitary anomalies (Bear et al., 2014). These genotype-phenotype correlations have  
21 contributed to facilitate molecular analysis and genetic counseling for HPE.  
22  
23  
24  
25  
26  
27  
28

29  
30 Initially, Sanger sequencing has successfully allowed establishing molecular diagnoses for about 20 %  
31 of HPE patients present in our cohort (Mercier et al., 2011). In order to explain, at least part of the  
32 remaining 80 % of unsolved cases, we have searched for microdeletions in the major HPE genes  
33 (*SHH*, *ZIC2*, *SIX3* and *TGIF1*) first by quantitative multiplex PCR of short fluorescent fragments  
34 (QMPSF) and then by multiplex ligation-dependent probe amplification (MLPA). Deletions in HPE  
35 genes were thereby shown to be a common cause of HPE in up to 8.5 % of fetuses and in 5% in our  
36 whole cohort (Bendavid et al., 2006).  
37  
38  
39

40  
41 In 2006, the combination of these different approaches allowed us to diagnose molecularly 25 % of  
42 our patients, very similar to the success rate of our American colleagues (Roessler, El-Jaick, et al.,  
43 2009; Solomon et al., 2010, 2012). As 75 % of cases remained unsolved, we and others in the field  
44 have considered alternative genetic causes of HPE.  
45  
46  
47

#### 48 *Chromosomal abnormalities and copy number variants in HPE*

49  
50 Since 2006, a pangenomic technique named comparative genomic hybridization (CGH) array has  
51 been used to screen the entire genome for copy number variations (CNVs). The first study we carried  
52 out during 2006-2009 revealed an impressively high rate of chromosomal rearrangements in HPE  
53 patients (22%), of which 14 % occurred *de novo* and 8 % were inherited (Bendavid et al., 2009, 2010).  
54 Furthermore, the observation of these CNVs can also lead to the detection of parental-balanced  
55  
56  
57  
58  
59  
60

translocations and can subsequently improve prenatal diagnosis in such families.

In addition, these CNVs involved novel potential HPE loci. Despite relatively low recurrence rates of CNVs, overlapping 6qter region deletions among 4 unrelated patients allowed identification of a ligand of the NOTCH signaling pathway, *Delta-like 1 (DLL1)* as candidate gene (Dupé et al., 2011). Subsequent detection of a nucleotide-based variant in a distinct patient provided further evidence for *DLL1* as HPE gene, and, together with expression and functional studies in vertebrates (Ratié et al., 2013; Ware, Hamdi-Rozé, & Dupé, 2014), allowed defining Notch as a novel signaling pathway involved in HPE.

In addition, microrearrangements found in unique cases, pointed to candidate genes such as *SIX6* and *OTX2*, which are both implicated in early brain development (Jean, Bernier, & Gruss, 1999; Jin, Harpal, Ang, & Rossant, 2001). Another study using a similar approach has also highlighted *OTX2* as a candidate gene (Rosenfeld et al., 2010).

Since this work, CGH-array has been and still is part of our systematic molecular screening of HPE patients. The novel detected CNVs are listed in Table II. The proportion of CNVs observed in this second period (2010-2017) is reduced as compared to that of our previous study (Bendavid et al., 2009). The rate of disease-relevant CNVs is now shown to be 10 %, half of which being *de novo*. Several of these rearrangements are recurrently observed in cases of intellectual disability, such as 2.6 Mb-microdeletion of 22q11.21 (proximal deletion) corresponding to DiGeorge syndrome (Burnside, 2015), 16p11.2 microduplication that confers susceptibility to autism (Fernandez et al., 2010), 16p13.11 encompassing the *NDE1* gene involved in brain neurogenesis and rhombencephalosynapsis (Bakircioglu et al., 2011; Démurger et al., 2013) and 15q11.2 microdeletion emerging as one of the most common cytogenetic abnormalities in intellectual disability and autism spectrum disorder (Butler, 2017). These deletions and duplications are thus at the origin of other neurodevelopmental disorders but are not sufficient to fully explain HPE. Nevertheless, CNV detection has increased the diagnostic yield from 25 % to 35 % in our cohort.

#### Next-generation sequencing (NGS) methods and their use for HPE diagnosis

The discovery of *SHH* in 1996 was followed by that of other genes - *ZIC2*, *SIX3*, *TGIF1* and *GLI2*. Since then, subsequent studies of the pathways implicating these major genes have contributed to the identification of additional HPE genes (Table I). Variants in genes involved in the SHH signaling pathway - *PTCH1*, *DISP1*, *CDON*, *GAS1*, *BOC* and *SUFU* - were described in some HPE patients (Bae et al., 2011; Dubourg et al., 2016; M. Hong et al., 2017; Ming et al., 2002; Pineda-Alvarez et al., 2012; Roessler, Ma, et al., 2009). A few variants have been described in *NODAL*, *TDGF1*, *FOXH1*, which encode proteins belonging to the Nodal/TGF-beta pathway (de la Cruz et al., 2002; Roessler et al., 2008; Roessler, Pei, et al., 2009). The Fibroblast Growth Factor pathway has also been implicated in

1  
2  
3 HPE through variants in *FGF8* and its receptor *FGFR1* (Arauz et al., 2010; Simonis et al., 2013). More  
4 recently, variants in *STIL*, a gene implicated in the formation of the primary cilia, were also described  
5 in HPE families (Kakar et al., 2015; Mouden et al., 2015). These are minor genes as they are reported  
6 in less than 1 % of HPE cases. Importantly, all these genes have in common the ability to affect SHH  
7 activity (Sun et al., 2014; Xavier et al., 2016).  
8

9  
10 Taking advantage of next-generation sequencing (NGS) in 2010, we established the first gene-panel  
11 sequencing method that targeted all known HPE genes (Dubourg et al., 2016). At the time we are  
12 writing this manuscript, more than 300 HPE patients have been tested. This study revealed that *SHH*,  
13 *ZIC2*, *SIX3* and *GLI2* retain their position of major genes and *TGIF1* is relegated to the minor gene  
14 group. Furthermore, the identification of numerous variants in *FGF8* and *FGFR1* strengthens the  
15 involvement of FGF signaling in HPE (Figure 1B). Recent functional analysis in Zebrafish has confirmed  
16 the contribution of *FGF8* variants in HPE (Hong et al., 2016; Hong, Hu, Roessler, Hu, & Muenke, 2018)  
17 in accordance with the known function of FGF signaling during the specification of the dorso-ventral  
18 axis of the forebrain (Storm et al., 2006).  
19

20  
21 From the results we obtained over the years from our 1,420 probands, the 10 first-ranked genes  
22 involved are *SHH* (5.4%), *ZIC2* (5.2%), *GLI2* (3.2%), *SIX3* (3.0%), *FGF8* (2.5%), *FGFR1* (2.0%), *DISP1*  
23 (1.2%), *DLL1* (1.2%) and *TGIF1* (0.9%) (Figure 2; Table I). Some rare deleterious variants have been  
24 found in *SUFU*, a regulator of the Sonic-hedgehog-signaling pathway (Dubourg et al., 2016). By  
25 contrast, we did not detect any pathogenic variants in the following minor genes: *PTCH1*, *NODAL*,  
26 *GAS1*, *TDGF1*, *CDON*, and *FOXH1*. To date, only a small number of variants have been reported for  
27 these genes (Bae et al., 2011; de la Cruz et al., 2002; Ming et al., 2002; Roessler et al., 2008; Roessler,  
28 Pei, et al., 2009). Therefore, more data need to be collected to unambiguously assign these genes to  
29 HPE etiology.  
30  
31

32  
33 As NGS technology evolved and became more accessible, whole exome sequencing (WES) is now  
34 routinely used to investigate novel HPE patients (see paragraph below). We expect this new  
35 approach will allow us not only to increase the diagnostic yield but also to identify novel HPE genes.  
36 Along the same lines, we are now establishing whole genome sequencing (WGS) approach in order to  
37 identify other alterations located in the noncoding part of the genome (~98 %) that has remained  
38 largely unexplored until now in the context of HPE.  
39  
40

41  
42 An important observation has emerged from our experience as clinical reference center for HPE.  
43 When comparing the percentage of positive diagnoses between 2010 and 2017 it appears  
44 surprisingly stable (about 35 %), despite the fact that sequencing technology has improved and that  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the number of HPE genes has increased. A closer examination of our data indicates that the fraction  
4 of patients with a CNV or with a variant in one of the major genes (*SHH*, *ZIC2* and *SIX3*) has been  
5 reduced by half as compared to that of 2010. Paradoxically, this reduction of cases is due to the  
6 increase of knowledge in diagnosis of HPE. Indeed, more and more clinical genetic centers are now  
7 able to perform their own molecular diagnoses for HPE. When a deleterious variant is found in one of  
8 the major HPE genes or when there is a CNV, the patient is not systematically referred to the  
9 reference center (i.e., Rennes, France) anymore. In contrast, when a molecular diagnosis could not  
10 be established, the patient data are sent to us for further investigation. As a consequence, the  
11 proportion of cases with an alteration in the major HPE genes has decreased in our cohort, which  
12 explains why our success rate of molecular diagnosis has remained stable over the years.  
13  
14  
15  
16  
17  
18  
19

### 20 **Modes of inheritance in HPE**

21 In 1996, we initiated an epidemiologic study on 258 HPE cases and concluded that for non-syndromic  
22 and non-chromosomal HPE, the most compatible mode of transmission was autosomal dominant  
23 with incomplete penetrance and a variable expressivity (Odent, Le Marec, Munnich, Le Merrer, &  
24 Bonaïti-Pellié, 1998).  
25  
26

27 In HPE, the analysis of the first four major genes revealed that in most of the cases (70 % for *SHH* and  
28 *SIX3*) the variants were inherited from a parent who was asymptomatic or only mildly affected  
29 (microform HPE). By classic textbook definitions, autosomal dominant inheritance is defined as the  
30 transmission of disease from an affected parent to an affected offspring. In this model, half of this  
31 parent's offspring is expected to be affected. Our observations show that this model (and ratios of  
32 affected offspring) does not appear to apply to HPE. Furthermore, although as many as 17 genes  
33 have been linked to HPE, variants in these genes collectively explain only 25 % of all HPE cases. It  
34 suggests that HPE is a complex disease with an increasing number of causative genes for which  
35 inheritance can vary depending of the affected gene as well as other related factors. This observation  
36 stresses the need for clarifying potential modes of its inheritance. In this section, we present  
37 different cases from our cohort and discuss their corresponding inheritance pattern.  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 ***De novo* versus inherited variants in HPE**

48 Systematic sequencing of the major HPE genes has shown a high proportion of *de novo* variants in  
49 *ZIC2* (70 %), *SHH* (30 %) and *SIX3* (30 %) (Figure 3 and Mercier et al., 2011). Thus, *de novo* variants are  
50 implicated in numerous sporadic HPE cases. In accordance with the essential role of these genes in  
51 early brain development, these *de novo* variants are loss-of-function and tend to be more deleterious  
52 than inherited ones (Roessler, El-Jaick, et al., 2009).  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In our cohort, 50 % of *FGFR1* variants appeared *de novo*. Adding to complexity, *FGFR1* is prone to  
4 mosaicism as we could show in one family in which a patient's father presents an attenuated HPE  
5 phenotype (Dubourg et al., 2016). Interestingly, cases of mosaicism involving *FGFR1* were described  
6 in other diseases like Hartsfield syndrome and encephalocraniocutaneous lipomatosis (Bennett et al.,  
7 2016; Dhamija et al., 2014). It should be noted that mosaic variants could be overlooked depending  
8 on the type of tissue tested and on the detection method (Braunholz et al., 2015), which could  
9 artificially increase the proportion of *de novo* variants.  
10  
11  
12  
13

### 14 15 **Rare examples of autosomal recessive inheritance in HPE patients**

16 In 2007, first case of recessive inheritance was described, involving two compound heterozygous  
17 variants in *TGIF1* (El-Jaick et al., 2007). Then, homozygous variant in *FGF8* was identified in one  
18 consanguineous HPE family (McCabe et al., 2011). More recently, another case of recessive  
19 inheritance involving *FGF8* was described (Hong et al., 2018). This *FGF8* variant was functionally  
20 validated and shown to be hypomorph, which is consistent with the indispensable role of FGF8  
21 during early development (Sun, Meyers, Lewandoski, & Martin, 1999). A severe loss of function is  
22 probably not compatible with embryonic development.  
23  
24  
25  
26  
27

28 Still, consanguineous families should predispose descendants to autosomal recessive gene  
29 combinations. Homozygosity mapping performed on 8 consanguineous HPE families from our cohort  
30 did not initially reveal any homozygous variants. Only by complementing mapping with WES we were  
31 able to detect in one of these families a homozygous hypomorphic variant for the gene *STIL* (Mouden  
32 et al., 2015). A homozygous nonsense variant of *STIL* was independently reported by others (Kakar et  
33 al., 2015). *STIL* is localized to centrioles where it participates in SHH signaling through its function in  
34 primary cilia biology and is known to be involved in microcephaly (David et al., 2014). Notably, in  
35 these two families, HPE is transmitted as a recessive trait associated with severe microcephaly. As no  
36 additional variant of *STIL* was described on more than 100 HPE patients tested (Karkera et al., 2002;  
37 Mouden et al., 2015), *STIL* gene therefore belongs to the minor HPE genes.  
38  
39  
40  
41  
42  
43

44 We also described a female HPE patient displaying two different mutated *DISP1* alleles both inherited  
45 from her two healthy parents (Mouden et al., 2016). These missense variants in the exon 10 were  
46 predicted to be deleterious. *DISP1* is a protein that mediates the secretion of SHH, that is required  
47 for long-range cell to cell signaling (Tian, Jeong, Harfe, Tabin, & McMahon, 2005). This patient  
48 presents a localized fusion of forebrain hemispheres (mild form of HPE). We believe that  
49 hypomorphic effect of *DISP1* missense variant impacts SHH secretion to such an extent that global  
50 SHH signaling is decreased to pathological level.  
51  
52  
53  
54

55 All cases of autosomal recessive inheritance reported so far involve unaffected parents and concern  
56 minor HPE genes (Figure 3). Despite systematic sequencing of the major genes (*SHH*, *ZIC2* and *SIX3*)  
57  
58  
59  
60

1  
2  
3 in our 1420 probands and others (Roessler, Vélez, Zhou, & Muenke, 2012), no recessive case has  
4 been reported for these genes. It suggests that homozygous variants in major genes are not  
5 compatible with embryonic development, which is fully consistent with their crucial roles during  
6 early developmental stages (Geng & Oliver, 2009; Schachter & Krauss, 2008) and may explain why  
7 recessive inheritance is rare in HPE.  
8  
9

### 10 11 12 **Oligogenic inheritance**

13 As presented above, variants in HPE genes are frequently inherited from a parent without a typical  
14 HPE phenotype (Mercier et al., 2011). Within a given family we observed a large phenotypic  
15 heterogeneity between the different variant carriers, illustrating the incomplete expressivity of these  
16 variants (Kruszka, Hart, Hadley, Muenke, & Habal, 2015; Mercier et al., 2011; Solomon et al., 2010;  
17 Stokes et al., 2018). These observations support the hypothesis that in these families variant in one  
18 HPE-related gene is necessary but not sufficient for the disease to occur, which implies more variants  
19 are required for complete phenotypic spectrum. This oligogenic mode of inheritance has already  
20 been proposed by our colleagues, who referred to it as "autosomal dominant with modifier effects"  
21 (S. Hong et al., 2016; M. Hong et al., 2017). In this oligogenic model, penetrance and expressivity of  
22 existing heterozygous variant is modulated by variants in other genes associated with HPE. Such a  
23 synergistic effect between distinct deleterious genetic events is now well-documented in several  
24 other hereditary developmental diseases (e.g, Alport, Bardet-Biedl and Kallman Syndromes) (Maione  
25 et al., 2018; Mencarelli et al., 2015; M'hamdi et al., 2014). In a similar manner, HPE could result from  
26 cumulated effects of distinct variants (Mercier, 2013). The use of animal models has reinforced this  
27 possibility. Numerous examples of double heterozygous mutant mice displaying HPE-like phenotypes  
28 provided evidence for oligogenism by implicating genes controlling either the same or distinct  
29 signaling pathways (Krauss, 2007).  
30  
31

32 For years, when a patient presented a deleterious variant in HPE gene, the analysis was interrupted  
33 because a likely genetic cause for the disease had been felt to be found. We believe it explains why  
34 rare HPE cases compatible with oligogenism have been reported so far (Ming & Muenke, 2002).  
35

36 High-throughput sequencing and genomic technologies provided a unique opportunity to address  
37 this oligogenic inheritance in HPE. Thanks to WES, we have recently started to address the presence  
38 of additional events in HPE patients with a known variant in a HPE gene. Some of our most recent  
39 unpublished results on the subject are presented below.  
40  
41

### 42 43 44 *Examples of digenic inheritance in HPE*

1  
2  
3 Digenic inheritance is the simplest form of inheritance for genetically complex diseases. Systematic  
4 sequencing of major HPE genes, have described isolated cases with variants in two genes (e.g.,  
5 *SHH/ZIC2*; *SHH/TGIF*) (Ming & Muenke, 2002). We also reported several cases of chromosomal  
6 rearrangement (CNV) associated with variant in HPE-related gene (Mercier et al., 2011).  
7

8  
9 In one family, presented in figure 2A, deleterious variants in both *SHH* and *DISP1* co-segregated with  
10 the disease, while relatives carrying variant only in either *SHH* or *DISP1* presented a mild or no  
11 disease phenotype (Mouden et al., 2016). This first digenic case in a family with several HPE patients  
12 prompted us to consider and further investigate digenic inheritance in families with HPE. This  
13 hypothesis was significantly reinforced by our experience with HPE genes routinely analyzed by  
14 targeted NGS. This study revealed that out of 257 HPE probands, 16 % of the variants used for  
15 diagnosis were found in association with a second variant (e.g., *FGF8/FGFR1*, *FGF8/DLL1*, *DLL1/SHH*,  
16 *DISP1/SUFU*) (Dubourg et al, 2016). More recently, two more cases of digenism were reported  
17 (*ZIC2/BOC* and *TGIF/BOC*) in HPE patients (Hong et al., 2017). Considering the systematic use of NGS  
18 on HPE patients and the increasing number of HPE genes, we expect that digenic cases will continue  
19 to accumulate further.  
20  
21  
22  
23  
24  
25

### 26 27 Cases of oligogenic inheritance in HPE

28  
29 The increasing number of digenic cases provides novel insights into genetic etiology of HPE such as  
30 oligogenic inheritance. Oligogenic pattern has never been described in HPE, but is often suggested in  
31 other complex diseases such as ciliopathies (Reiter & Leroux, 2017), retinitis pigmentosa (Ali,  
32 Rahman, Cao, & Yuan, 2017), autism spectrum disorder (ASD) (Yin & Schaaf, 2017), amyotrophic  
33 lateral sclerosis (ALS) (Nguyen, Van Broeckhoven, & van der Zee, 2018), or porphyria (Lenglet et al.,  
34 2018). These disorders share with HPE high genetic and phenotypic heterogeneity as well as  
35 incomplete penetrance. We therefore considered oligogenic inheritance as a likely cause of HPE that  
36 may account for at least a substantial part of enigmatic cases.  
37  
38  
39  
40  
41

42  
43 With constantly evolving knowledge of disease genes and emergence of new analysis methods, it has  
44 become important to us to reanalyze systematically previous unsolved cases. In that aim, we  
45 reevaluated unsolved HPE families by taking into account the possibility of oligogenic inheritance.  
46 The study included families with no identified causal variant as well as families with variants in *SHH*,  
47 *ZIC2*, *SIX3* or *TGIF1* inherited from clinically unaffected/mildly affected parent. Parts of this  
48 unpublished work are presented and discussed hereafter.  
49  
50  
51

52  
53 We combined trio-based whole exome sequencing with deep clinical phenotyping of the patients.  
54 Variant analysis was further improved by a gene prioritization approach based on clinical ontologies  
55 and co-expression networks of known disease-related signaling pathways.  
56  
57  
58  
59  
60

1  
2  
3 In one family, presented in Figure 2B, we identified a variant in *SHH*, which was inherited from the  
4 mother presenting with hypotelorism. Considering oligogenic inheritance, we addressed whether  
5 paternal variants could contribute to HPE phenotype in combination with the *SHH* variant inherited  
6 from the mother. Indeed, our analysis revealed paternally inherited variants in two candidate HPE  
7 genes - *FAT1* and *NDST1*. Both variants were rare (minor allele frequency below 1 %) and were  
8 predicted deleterious by the majority of bioinformatics algorithms (CADD score > 20). *FAT1* is a  
9 protocadherin and its knockdown in mouse causes severe midline defects including HPE (Ciani, Patel,  
10 Allen, & French-Constant, 2003) and *NDST1* is an N-deacetylase sulfotransferase and the  
11 corresponding mice mutants exhibit reduced SHH signaling and HPE-like phenotype (Grobe, 2005).  
12 Additionally, clinical phenotyping and analysis of cross-species similarities provided further evidence  
13 of causality for these genes by revealing a strong overlap of clinical features between the patient and  
14 the *FAT1* (proboscis) and *NDST1* (eye defects) mutant mice. Finally, the segregation analysis showed  
15 that the combination of variants in *SHH/FAT1/NDST1* was exclusively found in the two affected  
16 individuals of this family (Figure 2B). This example nicely illustrates oligogenic inheritance in HPE  
17 where the disease results from accumulation of multiple variants in genes associated to HPE  
18 phenotypes and/or implicated in SHH signaling (Figure 3). We therefore pursue a systematic  
19 reevaluation of all unsolved HPE cases. We believe that numerous other genes will be characterized  
20 in patients with oligogenism transmission. An exciting future challenge will be to test experimentally  
21 the combined effect of these different variants on early brain development.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Our clinical approach**

36  
37 Over the last two decades, we have followed for prenatal diagnosis 26 HPE families affected by a first  
38 case of severe HPE carrying a variant in one of the major HPE gene. In 18 instances, we were able to  
39 reassure the parents after establishing the absence of the gene alteration in the fetus. Fetal MRI scan  
40 was normal later in pregnancy, and no child had medical problems after birth. A genetic alteration (in  
41 *SHH*, *SIX3* or *TGIF1*) was found in the 8 other cases: 5 children were born, either without brain  
42 malformation and asymptomatic, or presenting a less severe form than the proband as predicted by  
43 the fetal brain surveillance. Three pregnancies were interrupted after MRI scans showed HPE  
44 features.  
45  
46  
47  
48  
49

50  
51 Nowadays, even when a causative gene for HPE has been found in a patient, the molecular diagnosis  
52 is probably not fully established. In order to properly address the molecular diagnosis, it will be  
53 necessary to compare the detailed phenotypes of the different family members with the segregation  
54 of relevant rare variants. For practitioners involved in counseling, an important consideration is how  
55 to communicate results of genetic analysis when potentially deleterious variants are identified but  
56  
57  
58  
59  
60

1  
2  
3 not yet functionally validated. Ideally, determining the contribution of each variant to the phenotype  
4 would be a condition for reliable genetic counseling in HPE families with oligogenic transmission.  
5  
6  
7

## 8 **Conclusion**

9  
10 In this review, we aimed to present the different patterns of inheritance of HPE in the light of our  
11 experience (Figure 3). In some cases, the disease is due to *de novo* variants; in rare cases the disease  
12 exhibits classical Mendelian inheritance with autosomal recessive transmission. In most cases, it  
13 emerges that the penetrance and the phenotypic variability have digenic or oligogenic origin. This  
14 complex genetic architecture will be better understood by analysis of hundreds of genes with NGS  
15 techniques on unsolved HPE cases. Our future challenge will be to differentiate rare variants that  
16 have significant impact on the observed phenotype from those with no effect.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1  
2  
3  
4  
5  
6 Ali, M. U., Rahman, M. S. U., Cao, J., & Yuan, P. X. (2017). Genetic characterization and disease  
7 mechanism of retinitis pigmentosa; current scenario. *3 Biotech*, *7*(4), 251.  
8 <https://doi.org/10.1007/s13205-017-0878-3>  
9
- 10 Arauz, R. F., Solomon, B. D., Pineda-Alvarez, D. E., Gropman, A. L., Parsons, J. A., Roessler, E., &  
11 Muenke, M. (2010). A Hypomorphic Allele in the FGF8 Gene Contributes to Holoprosencephaly and  
12 Is Allelic to Gonadotropin-Releasing Hormone Deficiency in Humans. *Molecular Syndromology*, *1*(2),  
13 59–66. <https://doi.org/10.1159/000302285>  
14
- 15 Bae, G.-U., Domené, S., Roessler, E., Schachter, K., Kang, J.-S., Muenke, M., & Krauss, R. S. (2011).  
16 Mutations in CDON, encoding a hedgehog receptor, result in holoprosencephaly and defective  
17 interactions with other hedgehog receptors. *American Journal of Human Genetics*, *89*(2), 231–240.  
18 <https://doi.org/10.1016/j.ajhg.2011.07.001>  
19
- 20 Bakircioglu, M., Carvalho, O. P., Khurshid, M., Cox, J. J., Tuysuz, B., Barak, T., ... Woods, C. G.  
21 (2011). The essential role of centrosomal NDE1 in human cerebral cortex neurogenesis. *American*  
22 *Journal of Human Genetics*, *88*(5), 523–535. <https://doi.org/10.1016/j.ajhg.2011.03.019>  
23
- 24 Bamshad, M. J., Ng, S. B., Bigham, A. W., Tabor, H. K., Emond, M. J., Nickerson, D. A., &  
25 Shendure, J. (2011). Exome sequencing as a tool for Mendelian disease gene discovery. *Nature*  
26 *Reviews. Genetics*, *12*(11), 745–755. <https://doi.org/10.1038/nrg3031>  
27
- 28 Barr, M., Hanson, J. W., Currey, K., Sharp, S., Toriello, H., Schmickel, R. D., & Wilson, G. N.  
29 (1983). Holoprosencephaly in infants of diabetic mothers. *The Journal of Pediatrics*, *102*(4), 565–568.  
30
- 31 Bear, K. A., Solomon, B. D., Antonini, S., Arnhold, I. J. P., França, M. M., Gerkes, E. H., ... Muenke,  
32 M. (2014). Pathogenic mutations in GLI2 cause a specific phenotype that is distinct from  
33 holoprosencephaly. *Journal of Medical Genetics*, *51*(6), 413–418. [https://doi.org/10.1136/jmedgenet-](https://doi.org/10.1136/jmedgenet-2013-102249)  
34 [2013-102249](https://doi.org/10.1136/jmedgenet-2013-102249)  
35
- 36 Bendavid, C., Dubourg, C., Gicquel, I., Pasquier, L., Saugier-Verber, P., Durou, M.-R., ... David, V.  
37 (2006). Molecular evaluation of fetuses with holoprosencephaly shows high incidence of  
38 microdeletions in the HPE genes. *Human Genetics*, *119*(1–2), 1–8. [https://doi.org/10.1007/s00439-](https://doi.org/10.1007/s00439-005-0097-6)  
39 [005-0097-6](https://doi.org/10.1007/s00439-005-0097-6)  
40
- 41 Bendavid, C., Dupé, V., Rochard, L., Gicquel, I., Dubourg, C., & David, V. (2010).  
42 Holoprosencephaly: An update on cytogenetic abnormalities. *American Journal of Medical Genetics.*  
43 *Part C, Seminars in Medical Genetics*, *154C*(1), 86–92. <https://doi.org/10.1002/ajmg.c.30250>  
44
- 45 Bendavid, C., Rochard, L., Dubourg, C., Seguin, J., Gicquel, I., Pasquier, L., ... David, V. (2009).  
46 Array-CGH analysis indicates a high prevalence of genomic rearrangements in holoprosencephaly: an  
47 updated map of candidate loci. *Human Mutation*, *30*(8), 1175–1182.  
48 <https://doi.org/10.1002/humu.21016>  
49
- 50 Bennett, J. T., Tan, T. Y., Alcantara, D., Tétrault, M., Timms, A. E., Jensen, D., ... McDonnell, L. M.  
51 (2016). Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis.  
52 *American Journal of Human Genetics*, *98*(3), 579–587. <https://doi.org/10.1016/j.ajhg.2016.02.006>  
53
- 54 Braunholz, D., Obieglo, C., Parenti, I., Pozojevic, J., Eckhold, J., Reiz, B., ... Kaiser, F. J. (2015).  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Hidden mutations in Cornelia de Lange syndrome limitations of sanger sequencing in molecular  
4 diagnostics. *Human Mutation*, 36(1), 26–29. <https://doi.org/10.1002/humu.22685>
- 5  
6 Bruel, A.-L., Franco, B., Duffourd, Y., Thevenon, J., Jegou, L., Lopez, E., ... Thauvin-Robinet, C.  
7 (2017). Fifteen years of research on oral-facial-digital syndromes: from 1 to 16 causal genes. *Journal*  
8 *of Medical Genetics*, 54(6), 371–380. <https://doi.org/10.1136/jmedgenet-2016-104436>
- 9  
10 Burnside, R. D. (2015). 22q11.21 Deletion Syndromes: A Review of Proximal, Central, and Distal  
11 Deletions and Their Associated Features. *Cytogenetic and Genome Research*, 146(2), 89–99.  
12 <https://doi.org/10.1159/000438708>
- 13  
14 Butler, M. G. (2017). Clinical and genetic aspects of the 15q11.2 BP1-BP2 microdeletion disorder.  
15 *Journal of Intellectual Disability Research: JIDR*, 61(6), 568–579. <https://doi.org/10.1111/jir.12382>
- 16  
17 Ciani, L., Patel, A., Allen, N. D., & French-Constant, C. (2003). Mice lacking the giant protocadherin  
18 mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia  
19 phenotype. *Molecular and Cellular Biology*, 23(10), 3575–3582.
- 20  
21 Cohen, M. M. (2006). Holoprosencephaly: clinical, anatomic, and molecular dimensions. *Birth*  
22 *Defects Research. Part A, Clinical and Molecular Teratology*, 76(9), 658–673.  
23 <https://doi.org/10.1002/bdra.20295>
- 24  
25 David, A., Liu, F., Tibelius, A., Vulprecht, J., Wald, D., Rothermel, U., ... Krämer, A. (2014). Lack of  
26 centrioles and primary cilia in STIL(-/-) mouse embryos. *Cell Cycle (Georgetown, Tex.)*, 13(18),  
27 2859–2868. <https://doi.org/10.4161/15384101.2014.946830>
- 28  
29 de la Cruz, J. M., Bamford, R. N., Burdine, R. D., Roessler, E., Barkovich, A. J., Donnai, D., ...  
30 Muenke, M. (2002). A loss-of-function mutation in the CFC domain of TDGF1 is associated with  
31 human forebrain defects. *Human Genetics*, 110(5), 422–428. [https://doi.org/10.1007/s00439-002-](https://doi.org/10.1007/s00439-002-0709-3)  
32 [0709-3](https://doi.org/10.1007/s00439-002-0709-3)
- 33  
34 Démurger, F., Pasquier, L., Dubourg, C., Dupé, V., Gicquel, I., Evain, C., ... David, V. (2013). Array-  
35 CGH Analysis Suggests Genetic Heterogeneity in Rhombencephalosynapsis. *Molecular*  
36 *Syndromology*, 4(6), 267–272. <https://doi.org/10.1159/000353878>
- 37  
38 Dhamija, R., Kirmani, S., Wang, X., Ferber, M. J., Wieben, E. D., Lazaridis, K. N., & Babovic-  
39 Vuksanovic, D. (2014). Novel de novo heterozygous FGFR1 mutation in two siblings with Hartsfield  
40 syndrome: a case of gonadal mosaicism. *American Journal of Medical Genetics. Part A*, 164A(9),  
41 2356–2359. <https://doi.org/10.1002/ajmg.a.36621>
- 42  
43 Dubourg, C., Bendavid, C., Pasquier, L., Henry, C., Odent, S., & David, V. (2007).  
44 Holoprosencephaly. *Orphanet Journal of Rare Diseases*, 2, 8. <https://doi.org/10.1186/1750-1172-2-8>
- 45  
46 Dubourg, C., Carré, W., Hamdi-Rozé, H., Mouden, C., Roume, J., Abdelmajid, B., ... David, V.  
47 (2016). Mutational Spectrum in Holoprosencephaly Shows That FGF is a New Major Signaling  
48 Pathway. *Human Mutation*, 37(12), 1329–1339. <https://doi.org/10.1002/humu.23038>
- 49  
50 Dupé, V., Rochard, L., Mercier, S., Le Pétillon, Y., Gicquel, I., Bendavid, C., ... David, V. (2011).  
51 NOTCH, a new signaling pathway implicated in holoprosencephaly. *Human Molecular Genetics*,  
52 20(6), 1122–1131. <https://doi.org/10.1093/hmg/ddq556>
- 53  
54 El-Jaick, K. B., Powers, S. E., Bartholin, L., Myers, K. R., Hahn, J., Orioli, I. M., ... Muenke, M.
- 55  
56  
57  
58  
59  
60

- (2007). Functional analysis of mutations in TGIF associated with holoprosencephaly. *Molecular Genetics and Metabolism*, *90*(1), 97–111. <https://doi.org/10.1016/j.ymgme.2006.07.011>
- Fernandez, B. A., Roberts, W., Chung, B., Weksberg, R., Meyn, S., Szatmari, P., ... Scherer, S. W. (2010). Phenotypic spectrum associated with de novo and inherited deletions and duplications at 16p11.2 in individuals ascertained for diagnosis of autism spectrum disorder. *Journal of Medical Genetics*, *47*(3), 195–203. <https://doi.org/10.1136/jmg.2009.069369>
- Geng, X., & Oliver, G. (2009). Pathogenesis of holoprosencephaly. *The Journal of Clinical Investigation*, *119*(6), 1403–1413. <https://doi.org/10.1172/JCI38937>
- Grobe, K. (2005). Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. *Development*, *132*(16), 3777–3786. <https://doi.org/10.1242/dev.01935>
- Hahn, J. S., Barnes, P. D., Clegg, N. J., & Stashinko, E. E. (2010). Septopreoptic holoprosencephaly: a mild subtype associated with midline craniofacial anomalies. *AJNR. American Journal of Neuroradiology*, *31*(9), 1596–1601. <https://doi.org/10.3174/ajnr.A2123>
- Hong, M., Srivastava, K., Kim, S., Allen, B. L., Leahy, D. J., Hu, P., ... Muenke, M. (2017). BOC is a modifier gene in holoprosencephaly. *Human Mutation*, *38*(11), 1464–1470. <https://doi.org/10.1002/humu.23286>
- Hong, S., Hu, P., Marino, J., Hufnagel, S. B., Hopkin, R. J., Toromanović, A., ... Muenke, M. (2016). Dominant-negative kinase domain mutations in FGFR1 can explain the clinical severity of Hartsfield syndrome. *Human Molecular Genetics*, *25*(10), 1912–1922. <https://doi.org/10.1093/hmg/ddw064>
- Hong, S., Hu, P., Roessler, E., Hu, T., & Muenke, M. (2018). Loss-of-function mutations in FGF8 can be independent risk factors for holoprosencephaly. *Human Molecular Genetics*. <https://doi.org/10.1093/hmg/ddy106>
- Jean, D., Bernier, G., & Gruss, P. (1999). Six6 (Optx2) is a novel murine Six3-related homeobox gene that demarcates the presumptive pituitary/hypothalamic axis and the ventral optic stalk. *Mechanisms of Development*, *84*(1–2), 31–40.
- Jin, O., Harpal, K., Ang, S. L., & Rossant, J. (2001). Otx2 and HNF3beta genetically interact in anterior patterning. *The International Journal of Developmental Biology*, *45*(1), 357–365.
- Kakar, N., Ahmad, J., Morris-Rosendahl, D. J., Altmüller, J., Friedrich, K., Barbi, G., ... Borck, G. (2015). STIL mutation causes autosomal recessive microcephalic lobar holoprosencephaly. *Human Genetics*, *134*(1), 45–51. <https://doi.org/10.1007/s00439-014-1487-4>
- Karkera, J. D., Izraeli, S., Roessler, E., Dutra, A., Kirsch, I., & Muenke, M. (2002). The genomic structure, chromosomal localization, and analysis of SIL as a candidate gene for holoprosencephaly. *Cytogenetic and Genome Research*, *97*(1–2), 62–67. <https://doi.org/10.1159/000064057>
- Krauss, R. S. (2007). Holoprosencephaly: new models, new insights. *Expert Reviews in Molecular Medicine*, *9*(26), 1–17. <https://doi.org/10.1017/S1462399407000440>
- Kruszka, P., Hart, R. A., Hadley, D. W., Muenke, M., & Habal, M. B. (2015). Expanding the phenotypic expression of Sonic Hedgehog mutations beyond holoprosencephaly. *The Journal of Craniofacial Surgery*, *26*(1), 3–5. <https://doi.org/10.1097/SCS.0000000000001377>

- 1  
2  
3 Lacbawan, F., Solomon, B. D., Roessler, E., El-Jaick, K., Domené, S., Vélez, J. I., ... Muenke, M.  
4 (2009). Clinical spectrum of SIX3-associated mutations in holoprosencephaly: correlation between  
5 genotype, phenotype and function. *Journal of Medical Genetics*, 46(6), 389–398.  
6 <https://doi.org/10.1136/jmg.2008.063818>  
7
- 8 Lenglet, H., Schmitt, C., Grange, T., Manceau, H., Karboul, N., Bouchet-Crivat, F., ... Gouya, L.  
9 (2018). From a dominant to an oligogenic model of inheritance with environmental modifiers in acute  
10 intermittent porphyria. *Human Molecular Genetics*, 27(7), 1164–1173.  
11 <https://doi.org/10.1093/hmg/ddy030>  
12
- 13 Maione, L., Dwyer, A. A., Francou, B., Guiochon-Mantel, A., Binart, N., Bouligand, J., & Young, J.  
14 (2018). GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic  
15 hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation  
16 sequencing. *European Journal of Endocrinology*, 178(3), R55–R80. <https://doi.org/10.1530/EJE-17-0749>  
17  
18
- 19 McCabe, M. J., Gaston-Massuet, C., Tziaferi, V., Gregory, L. C., Alatzoglou, K. S., Signore, M., ...  
20 Dattani, M. T. (2011). Novel FGF8 mutations associated with recessive holoprosencephaly,  
21 craniofacial defects, and hypothalamo-pituitary dysfunction. *The Journal of Clinical Endocrinology*  
22 *and Metabolism*, 96(10), E1709-1718. <https://doi.org/10.1210/jc.2011-0454>  
23  
24
- 25 Mencarelli, M. A., Heidet, L., Storey, H., van Geel, M., Knebelmann, B., Fallerini, C., ... Renieri, A.  
26 (2015). Evidence of digenic inheritance in Alport syndrome. *Journal of Medical Genetics*, 52(3), 163–  
27 174. <https://doi.org/10.1136/jmedgenet-2014-102822>  
28
- 29 Mercier, S., Dubourg, C., Garcelon, N., Campillo-Gimenez, B., Gicquel, I., Belleguic, M., ... Odent,  
30 S. (2011). New findings for phenotype-genotype correlations in a large European series of  
31 holoprosencephaly cases. *Journal of Medical Genetics*, 48(11), 752–760.  
32 <https://doi.org/10.1136/jmedgenet-2011-100339>  
33
- 34 M'hamdi, O., Redin, C., Stoetzel, C., Ouertani, I., Chaabouni, M., Maazoul, F., ... Chaabouni, H.  
35 (2014). Clinical and genetic characterization of Bardet-Biedl syndrome in Tunisia: defining a strategy  
36 for molecular diagnosis. *Clinical Genetics*, 85(2), 172–177. <https://doi.org/10.1111/cge.12129>  
37  
38
- 39 Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., ... Muenke, M.  
40 (2002). Mutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with  
41 holoprosencephaly. *Human Genetics*, 110(4), 297–301. <https://doi.org/10.1007/s00439-002-0695-5>  
42
- 43 Ming, J. E., & Muenke, M. (2002). Multiple hits during early embryonic development: digenic  
44 diseases and holoprosencephaly. *American Journal of Human Genetics*, 71(5), 1017–1032.  
45 <https://doi.org/10.1086/344412>  
46
- 47 Mouden, C., Dubourg, C., Carré, W., Rose, S., Quelin, C., Akloul, L., ... David, V. (2016). Complex  
48 mode of inheritance in holoprosencephaly revealed by whole exome sequencing. *Clinical Genetics*,  
49 89(6), 659–668. <https://doi.org/10.1111/cge.12722>  
50
- 51 Mouden, Charlotte, Tayrac, M. de, Dubourg, C., Rose, S., Carré, W., Hamdi-Rozé, H., ... David, V.  
52 (2015). Homozygous STIL Mutation Causes Holoprosencephaly and Microcephaly in Two Siblings.  
53 *PLOS ONE*, 10(2), e0117418. <https://doi.org/10.1371/journal.pone.0117418>  
54
- 55 Muenke, M., & Beachy, P. A. (2000). Genetics of ventral forebrain development and  
56  
57  
58  
59  
60

1  
2  
3 holoprosencephaly. *Current Opinion in Genetics & Development*, 10(3), 262–269.

4 Nanni, L., Ming, J. E., Bocian, M., Steinhaus, K., Bianchi, D. W., Die-Smulders, C., ... Muenke, M.  
5 (1999). The mutational spectrum of the sonic hedgehog gene in holoprosencephaly: SHH mutations  
6 cause a significant proportion of autosomal dominant holoprosencephaly. *Human Molecular Genetics*,  
7 8(13), 2479–2488.

8  
9  
10 Nguyen, H. P., Van Broeckhoven, C., & van der Zee, J. (2018). ALS Genes in the Genomic Era and  
11 their Implications for FTD. *Trends in Genetics: TIG*. <https://doi.org/10.1016/j.tig.2018.03.001>

12  
13 Odent, S., Le Marec, B., Munnich, A., Le Merrer, M., & Bonaïti-Pellié, C. (1998). Segregation  
14 analysis in nonsyndromic holoprosencephaly. *American Journal of Medical Genetics*, 77(2), 139–143.

15  
16 Pineda-Alvarez, D. E., Roessler, E., Hu, P., Srivastava, K., Solomon, B. D., Siple, C. E., ... Muenke,  
17 M. (2012). Missense substitutions in the GAS1 protein present in holoprosencephaly patients reduce  
18 the affinity for its ligand, SHH. *Human Genetics*, 131(2), 301–310. [https://doi.org/10.1007/s00439-](https://doi.org/10.1007/s00439-011-1078-6)  
19 011-1078-6

20  
21 Ratié, L., Ware, M., Barloy-Hubler, F., Romé, H., Gicquel, I., Dubourg, C., ... Dupé, V. (2013).  
22 Novel genes upregulated when NOTCH signalling is disrupted during hypothalamic development.  
23 *Neural Development*, 8, 25. <https://doi.org/10.1186/1749-8104-8-25>

24  
25 Reiter, J. F., & Leroux, M. R. (2017). Genes and molecular pathways underpinning ciliopathies.  
26 *Nature Reviews. Molecular Cell Biology*, 18(9), 533–547. <https://doi.org/10.1038/nrm.2017.60>

27  
28 Roessler, E., Belloni, E., Gaudenz, K., Jay, P., Berta, P., Scherer, S. W., ... Muenke, M. (1996).  
29 Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. *Nature Genetics*, 14(3), 357–  
30 360. <https://doi.org/10.1038/ng1196-357>

31  
32  
33 Roessler, Erich, Du, Y.-Z., Mullor, J. L., Casas, E., Allen, W. P., Gillessen-Kaesbach, G., ... Muenke,  
34 M. (2003). Loss-of-function mutations in the human GLI2 gene are associated with pituitary  
35 anomalies and holoprosencephaly-like features. *Proceedings of the National Academy of Sciences of*  
36 *the United States of America*, 100(23), 13424–13429. <https://doi.org/10.1073/pnas.2235734100>

37  
38 Roessler, Erich, El-Jaick, K. B., Dubourg, C., Vélez, J. I., Solomon, B. D., Pineda-Alvarez, D. E., ...  
39 Muenke, M. (2009). The mutational spectrum of holoprosencephaly-associated changes within the  
40 SHH gene in humans predicts loss-of-function through either key structural alterations of the ligand or  
41 its altered synthesis. *Human Mutation*, 30(10), E921-935. <https://doi.org/10.1002/humu.21090>

42  
43  
44 Roessler, Erich, Lacbawan, F., Dubourg, C., Paulussen, A., Herbergs, J., Hehr, U., ... Muenke, M.  
45 (2009). The full spectrum of holoprosencephaly-associated mutations within the ZIC2 gene in humans  
46 predicts loss-of-function as the predominant disease mechanism. *Human Mutation*, 30(4), E541-554.  
47 <https://doi.org/10.1002/humu.20982>

48  
49 Roessler, Erich, Ma, Y., Ouspenskaia, M. V., Lacbawan, F., Bendavid, C., Dubourg, C., ... Muenke,  
50 M. (2009). Truncating loss-of-function mutations of DISP1 contribute to holoprosencephaly-like  
51 microform features in humans. *Human Genetics*, 125(4), 393–400. [https://doi.org/10.1007/s00439-](https://doi.org/10.1007/s00439-009-0628-7)  
52 009-0628-7

53  
54 Roessler, Erich, Ouspenskaia, M. V., Karkera, J. D., Vélez, J. I., Kantipong, A., Lacbawan, F., ...  
55 Muenke, M. (2008). Reduced NODAL signaling strength via mutation of several pathway members  
56 including FOXH1 is linked to human heart defects and holoprosencephaly. *American Journal of*  
57

1  
2  
3 *Human Genetics*, 83(1), 18–29. <https://doi.org/10.1016/j.ajhg.2008.05.012>

4  
5 Roessler, Erich, Pei, W., Ouspenskaia, M. V., Karkera, J. D., Veléz, J. I., Banerjee-Basu, S., ...  
6 Muenke, M. (2009). Cumulative ligand activity of NODAL mutations and modifiers are linked to  
7 human heart defects and holoprosencephaly. *Molecular Genetics and Metabolism*, 98(1–2), 225–234.  
8 <https://doi.org/10.1016/j.ymgme.2009.05.005>

9  
10 Roessler, Erich, Vélez, J. I., Zhou, N., & Muenke, M. (2012). Utilizing prospective sequence analysis  
11 of SHH, ZIC2, SIX3 and TGIF in holoprosencephaly probands to describe the parameters limiting the  
12 observed frequency of mutant gene×gene interactions. *Molecular Genetics and Metabolism*, 105(4),  
13 658–664. <https://doi.org/10.1016/j.ymgme.2012.01.005>

14  
15 Rosenfeld, J. A., Ballif, B. C., Martin, D. M., Aylsworth, A. S., Bejjani, B. A., Torchia, B. S., &  
16 Shaffer, L. G. (2010). Clinical characterization of individuals with deletions of genes in  
17 holoprosencephaly pathways by aCGH refines the phenotypic spectrum of HPE. *Human Genetics*,  
18 127(4), 421–440. <https://doi.org/10.1007/s00439-009-0778-7>

19  
20 Ruiz i Altaba, A., Palma, V., & Dahmane, N. (2002). Hedgehog-Gli signalling and the growth of the  
21 brain. *Nature Reviews. Neuroscience*, 3(1), 24–33. <https://doi.org/10.1038/nrn704>

22  
23 Schachter, K. A., & Krauss, R. S. (2008). Murine models of holoprosencephaly. *Current Topics in*  
24 *Developmental Biology*, 84, 139–170. [https://doi.org/10.1016/S0070-2153\(08\)00603-0](https://doi.org/10.1016/S0070-2153(08)00603-0)

25  
26 Simonis, N., Migeotte, I., Lambert, N., Perazzolo, C., de Silva, D. C., Dimitrov, B., ... Vilain, C.  
27 (2013). FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly  
28 and ectrodactyly. *Journal of Medical Genetics*, 50(9), 585–592. [https://doi.org/10.1136/jmedgenet-](https://doi.org/10.1136/jmedgenet-2013-101603)  
29 2013-101603

30  
31 Solomon, B. D., Bear, K. A., Wyllie, A., Keaton, A. A., Dubourg, C., David, V., ... Muenke, M.  
32 (2012). Genotypic and phenotypic analysis of 396 individuals with mutations in Sonic Hedgehog.  
33 *Journal of Medical Genetics*, 49(7), 473–479. [https://doi.org/10.1136/jmedgenet-](https://doi.org/10.1136/jmedgenet-2012-101008)  
34 2012-101008

35  
36 Solomon, B. D., Mercier, S., Vélez, J. I., Pineda-Alvarez, D. E., Wyllie, A., Zhou, N., ... Muenke, M.  
37 (2010). Analysis of genotype-phenotype correlations in human holoprosencephaly. *American Journal*  
38 *of Medical Genetics. Part C, Seminars in Medical Genetics*, 154C(1), 133–141.  
39 <https://doi.org/10.1002/ajmg.c.30240>

40  
41 Stokes, B., Berger, S. I., Hall, B. A., Weiss, K., Martinez, A. F., Hadley, D. W., ... Muenke, M.  
42 (2018). SIX3 deletions and incomplete penetrance in families affected by holoprosencephaly.  
43 *Congenital Anomalies*, 58(1), 29–32. <https://doi.org/10.1111/cga.12234>

44  
45 Storm, E. E., Garel, S., Borello, U., Hebert, J. M., Martinez, S., McConnell, S. K., ... Rubenstein, J. L.  
46 R. (2006). Dose-dependent functions of Fgf8 in regulating telencephalic patterning centers.  
47 *Development (Cambridge, England)*, 133(9), 1831–1844. <https://doi.org/10.1242/dev.02324>

48  
49 Sun, L., Carr, A. L., Li, P., Lee, J., McGregor, M., & Li, L. (2014). Characterization of the human  
50 oncogene SCL/TAL1 interrupting locus (Stil) mediated Sonic hedgehog (Shh) signaling transduction  
51 in proliferating mammalian dopaminergic neurons. *Biochemical and Biophysical Research*  
52 *Communications*, 449(4), 444–448. <https://doi.org/10.1016/j.bbrc.2014.05.048>

53  
54 Sun, X., Meyers, E. N., Lewandoski, M., & Martin, G. R. (1999). Targeted disruption of Fgf8 causes  
55 failure of cell migration in the gastrulating mouse embryo. *Genes & Development*, 13(14), 1834–1846.

1  
2  
3 Tian, H., Jeong, J., Harfe, B. D., Tabin, C. J., & McMahon, A. P. (2005). Mouse *Disp1* is required in  
4 sonic hedgehog-expressing cells for paracrine activity of the cholesterol-modified ligand. *Development*  
5 (*Cambridge, England*), *132*(1), 133–142. <https://doi.org/10.1242/dev.01563>

6  
7 Ware, M., Hamdi-Rozé, H., & Dupé, V. (2014). Notch signaling and proneural genes work together to  
8 control the neural building blocks for the initial scaffold in the hypothalamus. *Frontiers in*  
9 *Neuroanatomy*, *8*, 140. <https://doi.org/10.3389/fnana.2014.00140>

10  
11 Xavier, G. M., Seppala, M., Barrell, W., Birjandi, A. A., Geoghegan, F., & Cobourne, M. T. (2016).  
12 Hedgehog receptor function during craniofacial development. *Developmental Biology*, *415*(2), 198–  
13 215. <https://doi.org/10.1016/j.ydbio.2016.02.009>

14  
15 Yin, J., & Schaaf, C. P. (2017). Autism genetics - an overview. *Prenatal Diagnosis*, *37*(1), 14–30.  
16 <https://doi.org/10.1002/pd.4942>

## 25 Figure legends

26  
27 **Figure 1.** Clinical and molecular details of the European HPE cohort

28 (A) Brain anomalies distribution in European HPE cohort (1,420 probands).

29 (B) Mutational spectrum of HPE.

30  
31 In blue, number of variants found in 2010. 164/642 (25.4 %) patients were found to harbor variants  
32 in *SHH*, *ZIC2*, *SIX3* or *TGIF1*. *GLI2* variants were identified in 3/208 patients (Mercier et al., 2011).

33  
34 In red, number of variants found in 2017. Molecular screening of major HPE genes in 1,420 patients  
35 revealed 207 variants in *SHH*, *ZIC2*, *SIX3* and *TGIF1*. Complementary screenings on a series of 302  
36 patients revealed 32 variants in *DLL1*, *FGF8*, *FGFR1*, *DISP1* and *GLI2*.

37  
38 (C) Contribution of CGH-array to molecular diagnosis. In 2010, CNVs were detected in 22 % of the  
39 260 patients analyzed by CGH-array, including 36 occurring *de novo*. In 2017, the screening of our  
40 entire cohort (1,420 patients) reported CNVs in 142 patients (10%), including 71 occurring *de novo*.

41  
42  
43  
44  
45 **Figure 2.** Examples of complex inheritance in HPE.

46 (A) Family presenting a digenic mode of transmission associating variants in *SHH* and *DISP1* (Mouden  
47 et al., 2016). Minor signs refer to microcephaly.

48 (B) Family presenting an oligogenic pattern with combined inherited variants in *SHH*, *FAT1* and  
49 *NDST1*. Minor signs refer to hypotelorism (father) and epicanthus (mother).

50  
51 Individuals marked with asterisk were analyzed by whole exome sequencing. NA: Not available for  
52 *DISP1* sequencing.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 3.** Different inheritance patterns for HPE are presented together with illustrative cases from our unpublished data.

For Peer Review

1  
2  
3 **TABLE I. List of HPE genes and corresponding percentages of variants found in our HPE cohort.**  
4

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Chromosome	Gene	NM	%
7	<i>SHH</i>	000193.2	5.4
13	<i>ZIC2</i>	007129.3	5.2
2	<i>GLI2</i>	005270.4	3.2
2	<i>SIX3</i>	005413.3	3.0
10	<i>FGF8</i>	033163.3	2.5
8	<i>FGFR1</i>	023110.2	2.0
1	<i>DISP1</i>	032890.3	1.2
6	<i>DLL1</i>	005618.3	1.2
18	<i>TGIF1</i>	170695.2	0.9
10	<i>SUFU</i>	016169.3	0.4
1	<i>STIL</i>	001048166.1	1 case/375
9	<i>GAS1</i>	002048.2	0
3	<i>TDGF1</i>	003212.3	0
11	<i>CDON</i>	016952.4	0
8	<i>FOXH1</i>	003923.2	0
10	<i>NODAL</i>	018055.4	0
3	<i>BOC</i>	001301861.1	Not tested

**TABLE II: Summary of chromosomal abnormalities in HPE cases**


Patient	Cytoband	Type of CNV	Start-End (GRCh37)	CNV size	Inheritance
1	1q43q44	del	242094954_249212668	7 Mb	Inherited from parental balanced t(1;3)
	3p25.2p22.1	dup	0_39848444	40 Mb	
2	2p15	del	61668439_61777447	109 kb	<i>De novo</i>
3	2p11.2	dup	85824180_86469217	645 kb	<i>De novo</i>
	16p13.11*	dup	15492317_16276115	784 kb	Inherited from father
4	3p22;20q11.2	balanced translocation	-	-	Inherited from mother
5	3q25.32	del	157105931_157154842	50 kb	Inherited from mother
6	4q12	del	55193357_58196685	3,00 Mb	ND
7	5q35.3	del	177296851_178323802	1 Mb	Inherited from mother
8	5q35.3	dup	178038828-179766520	1,73 Mb	Inherited
9	7p22.1	del	5399371_6871084	1,4 Mb	<i>De novo</i>
10	7p22.1	dup	5057686_5166175	108 kb	Inherited from father
11	8q23.3q24.11	del	117641330-118051191	410 kb	ND
12	Whole chromosome 8	dup in mosaic	0_146294098	146 Mb	<i>De novo</i>
13	10p15.3p14	del	136361-9946915	9,8 Mb	<i>De novo</i>
14	11q13.4	dup	74931870-75109882	178 kb	Inherited from mother
15	12q21.32	del	86984993_87656628	672 kb	ND
16	14q23.1	del	60950490_61006021	55 kb	Inherited from mother
17	14q23.1	dup	Unavailable data	900kb	Inherited from mother
18	15q11.2*	del	22765628-23208901	443 kb	Inherited from mother
19	16p13.11*	del	15492317_16267306	1,3 Mb	ND
	16p11.2*	dup	29652999_30197341	544 kb	Inherited from mother
20	18q22.1	dup	64152648_64324336	172 kb	Inherited from mother
21	19q13.42q13.43	dup	56228025_57744093	1,5 Mb	<i>De novo</i>
22	22q11.21*	del	20719112-21464119	745 kb	ND
23	22q11.21*	del	21081060_21505558	424 kb	<i>De novo</i>
24	22q11.21*	del	18894835_21464119	2,6 Mb	<i>De novo</i>
25	22q11.21*	del	18894835_21464119	2,6 Mb	<i>De novo</i>
26	22q11.21*	del	18651614_21801661	3,2 Mb	ND
27	Xq25q28	del	123176394-152515593	29,34 Mb	<i>De novo</i>

del = deletion; dup = duplication; ND = not determined; \*CNV (Copy number variation) usually observed in intellectual deficiency


**A** Distribution of brain anomalies in European HPE cohort



**B** Number of mutations in HPE genes 2010 / 2017




**C**




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

**A**




**B**



**Autosomal dominant (*de novo*)**


~35 %



*ZIC2* (70%)  
*FGFR1* (50%)  
*SHH* (30%)  
*SIX3* (30%)

**Autosomal recessive**


&lt;1 %



*STIL/STIL*  
*DISP1/DISP1*  
*TGIF1/TGIF1*  
*FGF8/FGF8*

**Digenism**

? %



*SHH/DISP1*  
*SIX3/PTCH1*  
*SHH/DLL1*  
*FGF8/FGFR1*  
 ...

**Oligogenism**

? %



*SHH/FAT1/NDST1*  
 ...

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47